Your browser doesn't support javascript.
loading
TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimer's disease-associated H157Y variant.
Thornton, Peter; Sevalle, Jean; Deery, Michael J; Fraser, Graham; Zhou, Ye; Ståhl, Sara; Franssen, Elske H; Dodd, Roger B; Qamar, Seema; Gomez Perez-Nievas, Beatriz; Nicol, Louise Sc; Eketjäll, Susanna; Revell, Jefferson; Jones, Clare; Billinton, Andrew; St George-Hyslop, Peter H; Chessell, Iain; Crowther, Damian C.
Afiliación
  • Thornton P; Neuroscience, Innovative Medicines and Early Development, AstraZeneca Granta Park, Cambridge, UK.
  • Sevalle J; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
  • Deery MJ; Cambridge Centre for Proteomics, University of Cambridge, Cambridge, UK.
  • Fraser G; Neuroscience, Innovative Medicines and Early Development, AstraZeneca Granta Park, Cambridge, UK.
  • Zhou Y; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
  • Ståhl S; AstraZeneca Translational Sciences Centre, Karolinska Institutet, Stockholm, Sweden.
  • Franssen EH; Neuroscience, Innovative Medicines and Early Development, AstraZeneca Granta Park, Cambridge, UK.
  • Dodd RB; Department of Clinical Neurosciences, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.
  • Qamar S; MedImmune Limited Granta Park, Cambridge, UK.
  • Gomez Perez-Nievas B; Department of Clinical Neurosciences, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.
  • Nicol LS; Neuroscience, Innovative Medicines and Early Development, AstraZeneca Granta Park, Cambridge, UK.
  • Eketjäll S; MedImmune Limited Granta Park, Cambridge, UK.
  • Revell J; Cardiovascular and Metabolic Diseases, Innovative Medicines and Early Development, AstraZeneca, ICMC, Huddinge, Sweden.
  • Jones C; MedImmune Limited Granta Park, Cambridge, UK.
  • Billinton A; MedImmune Limited Granta Park, Cambridge, UK.
  • St George-Hyslop PH; Neuroscience, Innovative Medicines and Early Development, AstraZeneca Granta Park, Cambridge, UK.
  • Chessell I; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada.
  • Crowther DC; Department of Clinical Neurosciences, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.
EMBO Mol Med ; 9(10): 1366-1378, 2017 10.
Article en En | MEDLINE | ID: mdl-28855301
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Glicoproteínas de Membrana / Receptores Inmunológicos / Enfermedad de Alzheimer / Proteolisis Tipo de estudio: Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: EMBO Mol Med Asunto de la revista: BIOLOGIA MOLECULAR Año: 2017 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Glicoproteínas de Membrana / Receptores Inmunológicos / Enfermedad de Alzheimer / Proteolisis Tipo de estudio: Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: EMBO Mol Med Asunto de la revista: BIOLOGIA MOLECULAR Año: 2017 Tipo del documento: Article País de afiliación: Reino Unido